Editorial classification note: Orforglipron is a synthetic small molecule (molecular weight ~883 g/mol; formula C48H48F2N10O5), not a peptide. It is included on PeptideWise as comparator context for our coverage of injectable peptide GLP-1 receptor agonists such as semaglutide, tirzepatide, and retatrutide.
What Is Foundayo (Orforglipron)?
Foundayo is the brand name for orforglipron (development code LY3502970), a once-daily oral tablet developed by Eli Lilly and Company. The U.S. Food and Drug Administration approved Foundayo on April 1, 2026, for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition.
The approval is notable on two regulatory dimensions. First, Foundayo is the first non-peptide oral GLP-1 receptor agonist approved by the FDA for chronic weight management. Second, it is the first new molecular entity to be approved under the FDA Commissioner's National Priority Voucher program, a pathway introduced to accelerate review of medicines addressing unmet public health needs. The voucher pathway resulted in approval approximately 50 days after Lilly's submission — substantially faster than the 294-day standard review timeline that would have applied under the original PDUFA date of January 20, 2027.
How Does Orforglipron Work?
Orforglipron activates the GLP-1 receptor — the same receptor targeted by injectable peptide drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). However, the molecular architecture is fundamentally different. Where peptide GLP-1 receptor agonists are large polypeptide chains structurally similar to native human GLP-1, orforglipron is a synthetic small molecule that binds the receptor at an allosteric site distinct from the native peptide binding pocket.
Once bound, orforglipron triggers the same downstream signaling cascade as native GLP-1: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release, slowed gastric emptying, and central appetite suppression via hypothalamic and brainstem pathways. The clinical effects — reduced hunger, earlier satiety, improved glycemic control, and weight loss — therefore resemble those of injectable GLP-1 receptor agonists.
Because orforglipron is not a peptide, it resists gastrointestinal proteolysis. This means it can be absorbed orally without the absorption-enhancer technology (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, or SNAC) and the strict fasting protocol required for oral semaglutide (Rybelsus). Foundayo can be taken at any time of day, with or without food, with no water restrictions.
What Did the ATTAIN-1 Trial Show?
ATTAIN-1 was the pivotal Phase 3 trial supporting Foundayo's FDA approval for chronic weight management. The 72-week, randomized, double-blind, placebo-controlled trial enrolled 3,127 adults with obesity or overweight plus at least one weight-related comorbidity (excluding type 2 diabetes).
- Mean weight loss (efficacy estimand, 36 mg dose): 12.4% (~27.3 lb / 12.4 kg) versus 0.9% with placebo at 72 weeks.
- Mean weight loss (treatment-regimen estimand, all doses): 6 mg arm: −6.5%; 12 mg arm: −8.4%; 36 mg arm: −11.2%; placebo: −2.1% (P<0.001 for all doses vs placebo).
- Categorical response rates at 36 mg: 54.6% achieved ≥10% weight loss; 36.0% achieved ≥15%; 18.4% achieved ≥20%.
- Cardiometabolic improvements: Significant reductions in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol versus placebo.
The full ATTAIN-1 results were published in the New England Journal of Medicine (Aronne et al., 2025; DOI: 10.1056/NEJMoa2511774). The companion ATTAIN-2 trial in adults with type 2 diabetes plus obesity or overweight was pooled with ATTAIN-1 for the FDA's safety analysis.
How Does Foundayo Compare to Injectable GLP-1 Drugs?
No head-to-head randomized controlled trials have been published comparing Foundayo to injectable semaglutide (Wegovy) or tirzepatide (Zepbound) at the time of FDA approval. The available evidence is limited to indirect comparison of trial results, which carries significant methodological caveats.
- Foundayo (orforglipron 36 mg, ATTAIN-1): ~11–12% mean body weight loss at 72 weeks.
- Semaglutide injection (2.4 mg, STEP 1): ~14.9% mean body weight loss at 68 weeks.
- Tirzepatide injection (15 mg, SURMOUNT-1): ~20.9% mean body weight loss at 72 weeks.
On magnitude of weight loss, Foundayo's efficacy appears meaningfully below tirzepatide and modestly below injectable semaglutide. Where Foundayo offers a clear differentiator is in administration: oral tablet rather than weekly injection, no fasting requirement, room-temperature storage, and conventional small-molecule manufacturing (which Lilly has cited as enabling larger-scale supply than peptide fermentation).
What Is the FDA-Labeled Dosing Schedule?
Per the Foundayo US Prescribing Information (April 2026), the labeled titration schedule is:
- Initiate at 0.8 mg once daily.
- Escalate to 2.5 mg after at least 30 days.
- Escalate to 5.5 mg after an additional 30 days.
- May escalate further to 9 mg, 14.5 mg, and 17.2 mg at 30-day intervals based on individual tolerability and clinical response.
- Maximum dose is reduced to 9 mg daily when co-administered with strong CYP3A4 inhibitors.
The slow titration schedule is designed to minimize gastrointestinal adverse events, which are most pronounced during dose escalation.
This dosing summary is provided for reference and educational context only. It is not medical advice. Foundayo is a prescription-only medication, and the appropriate dose for any individual must be determined by a licensed healthcare provider with full knowledge of that person's medical history, comorbidities, and concurrent medications.
What Are the Common Side Effects?
The adverse-event profile reported in ATTAIN-1 and pooled trial data is consistent with the GLP-1 receptor agonist drug class. The most frequently reported adverse events are gastrointestinal:
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Dyspepsia (indigestion)
- Abdominal pain and abdominal distension
- Eructation (belching) and flatulence
- Gastroesophageal reflux
Other reported adverse events include headache, fatigue, and hair loss. In ATTAIN-1, treatment discontinuation due to adverse events ranged from 5.3% to 10.3% across orforglipron dose arms, compared with 2.7% in the placebo arm — a meaningful tolerability gap that should be discussed with a prescriber.
What Are the Boxed Warnings and Contraindications?
Foundayo carries the same class boxed warning as other GLP-1 receptor agonists for the risk of thyroid C-cell tumors, based on rodent carcinogenicity findings with the GLP-1 drug class. It is worth noting that orforglipron is not pharmacologically active at the rodent GLP-1 receptor and did not produce thyroid C-cell tumors in rodent carcinogenicity studies; however, the human relevance of GLP-1 receptor agonist–associated rodent thyroid C-cell tumors remains undetermined, and the class warning is applied as a precaution.
Contraindications per the FDA label:
- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known serious hypersensitivity to orforglipron or any excipient in Foundayo.
Class-level risks noted in the label include pancreatitis, cholelithiasis (gallstone disease), acute kidney injury (typically secondary to dehydration from gastrointestinal adverse events), and the potential for hypoglycemia when used concurrently with insulin or sulfonylureas.
Cardiovascular outcomes data were not yet available at the time of approval; no cardiovascular outcomes trial (CVOT) has been reported for orforglipron. This contrasts with injectable semaglutide, which has positive CV outcomes data from the SELECT trial. Per April 2026 reporting, the FDA has requested additional post-marketing safety data from Lilly.
Why Is the Peptide vs. Small-Molecule Distinction Important?
For readers of an evidence-based peptide research site, the peptide-versus-small-molecule classification matters for several reasons:
- Pharmacology: Orforglipron's discovery validates the pharmacological hypothesis that the GLP-1 receptor can be activated by molecules with no structural resemblance to the native peptide. This opens a research direction where additional small-molecule agonists or biased agonists may produce different downstream signaling profiles than peptide drugs.
- Manufacturing: Peptide drugs require recombinant fermentation or solid-phase peptide synthesis — both expensive and capacity-limited. Small molecules can be manufactured at conventional pharmaceutical scale, which has obvious implications for global supply, pricing, and access.
- Stability: Small molecules generally tolerate broader storage conditions (room temperature, longer shelf life) than peptides, which often require cold-chain logistics.
- Editorial framing: Foundayo should not be described as a "peptide" in technical writing. It is a small-molecule agonist of a peptide hormone receptor. The same applies to any future small-molecule entrant in this class (Lilly's pipeline includes additional small-molecule incretin candidates).
What Should You Do With This Information?
If you are considering whether Foundayo or any GLP-1 receptor agonist is appropriate for you, the conversation belongs with a licensed prescribing clinician. Bring the published trial data, your full medical history, your goals, and your concerns. PeptideWise does not provide medical advice, recommend medications, or suggest doses. We summarize the published evidence so that informed conversations are easier to have.
If you would like to track an injection schedule, dose-titration milestones, or side-effect patterns for any GLP-1 protocol you have discussed with your clinician, our companion app PeptideTracker is built for exactly that workflow.